MRUS

Merus NV

Add to Watchlist

Advanced Chart

45.050

-0.230(-0.510%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

45.9899

Open

45.270

VWAP

45.23

Vol

345.24K

Mkt Cap

3.12B

Low

44.590

Amount

15.61M

EV/EBITDA(TTM)

Total Shares

67.37M

2.60B

EV/OCF(TTM)

P/S(TTM)

80.46

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

7.48M

-5.15%

-1.054

+78.58%

12.08M

+64.82%

-1.072

+32.39%

8.22M

-30.18%

-1.093

-25.14%

Estimates Revision

The market is revising Downward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by -19.11% over the past three months. During the same period, the stock price has changed by 8.37%.

Revenue Estimates for FY2025

Revise Downward

-19.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+10.57%

In Past 3 Month

Stock Price

Go Up

+8.37%

In Past 3 Month

15 Analyst Rating

98.49% Upside

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 89.42 USD with a low forecast of 67.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

0 Hold

0 Sell

Strong Buy

98.49% Upside

Current: 45.050

Low

67.00

Averages

89.42

High

110.00

98.49% Upside

Current: 45.050

Low

67.00

Averages

89.42

High

110.00

Needham

Ami Fadia

Strong Buy

Reiterates

$83

2025-04-09

Reason

Needham

Ami Fadia

Price Target

$83

2025-04-09

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

$109

2025-03-28

Reason

Guggenheim

Michael Schmidt

Price Target

$109

2025-03-28

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

$109

2025-03-18

Reason

Guggenheim

Michael Schmidt

Price Target

$109

2025-03-18

Reiterates

Strong Buy

Reason

B of A Securities

Tazeen Ahmad

Strong Buy

Maintains

$73 → $70

2025-03-10

Reason

B of A Securities

Tazeen Ahmad

Price Target

$73 → $70

2025-03-10

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$85

2025-03-03

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$85

2025-03-03

Reiterates

Strong Buy

Reason

Needham

Ami Fadia

Strong Buy

Maintains

$85 → $83

2025-02-28

Reason

Needham

Ami Fadia

Price Target

$85 → $83

2025-02-28

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Merus NV (MRUS.O) is -10.87, compared to its 5-year average forward P/E of -9.72. For a more detailed relative valuation and DCF analysis to assess Merus NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.72

Current PE

-10.87

Overvalued PE

-6.29

Undervalued PE

-13.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.52

Current EV/EBITDA

-6.70

Overvalued EV/EBITDA

-2.01

Undervalued EV/EBITDA

-9.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

35.21

Current PS

70.81

Overvalued PS

59.43

Undervalued PS

10.98

Financials

Annual

Quarterly

FY2024Q4

YoY :

+2.25%

9.14M

Total Revenue

FY2024Q4

YoY :

+86.47%

-88.65M

Operating Profit

FY2024Q4

YoY :

-48.59%

-30.92M

Net Income after Tax

FY2024Q4

YoY :

-56.73%

-0.45

EPS - Diluted

FY2024Q4

YoY :

+83.44%

-66.68M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

+56.13%

-519.37

FCF Margin - %

FY2024Q4

YoY :

-49.72%

-338.33

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

194.0K

USD

3-6

Months

0.0

USD

6-9

Months

270.0K

USD

0-12

Months

4.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.2M

Volume

6-9

Months

0.0

Volume

0-12

Months

4.4M

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.3M

Volume

Months

6-9

0.0

Volume

Months

0-12

10.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

194.0K

USD

3-6

Months

0.0

USD

6-9

Months

270.0K

USD

0-12

Months

4.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MRUS News & Events

Events Timeline

2025-02-27 (ET)

2025-02-27

16:15:43

Merus reports FY24 EPS ($3.35), consensus ($3.72)

2025-01-13 (ET)

2025-01-13

10:17:44

Biohaven enters multi-target collaboration with Merus

2025-01-13

04:59:18

Biohaven, Merus enter research pact and license agreement to develop three ADCs

News

4.0

04-09Benzinga

Needham Reiterates Buy on Merus, Maintains $83 Price Target

4.0

03-28Benzinga

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

4.0

03-03Business Insider

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), Merus (MRUS) and Agilent (A)

People Also Watch

RYAM

Rayonier Advanced Materials Inc

Invesco Mortgage Capital Inc

Evolv Technologies Holdings Inc

Flushing Financial Corp

Gladstone Investment Corp

FAQ

What is Merus NV (MRUS) stock price today?

The current price of MRUS is 45.05 USD — it has decreased -0.51 % in the last trading day.

MRUS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

MRUS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Merus NV (MRUS) stock price today?

What is Merus NV (MRUS)'s business?

What is the price predicton of MRUS Stock?

What is Merus NV (MRUS)'s revenue for the last quarter?

What is Merus NV (MRUS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Merus NV (MRUS)'s fundamentals?

How many employees does Merus NV (MRUS). have?

What is Merus NV (MRUS) market cap?